Back to products
Metabolic
New
Tirzepatide
Dual GIP / GLP-1 agonist
$179
AUD · 5mg vial
99.0% purity
COA included
Lyophilised
In stock
A first-in-class dual GIP and GLP-1 receptor agonist studied for metabolic and body composition research.
Research use only. Not for human consumption, diagnosis, or therapeutic use. For in-vitro and laboratory research purposes only.
- Dual GIP/GLP-1 agonism
- Studied for insulin sensitivity
- Sustained satiety signalling
- Body composition research
Tirzepatide is a synthetic peptide that acts as a dual agonist at both the GIP and GLP-1 receptors. Research focuses on its synergistic effects on insulin sensitivity, satiety, and adipose tissue.
Each vial is independently verified by LC-MS.
